

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	AVITA Medical Limited
ABN	28 058 466 523

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Perry
Date of last notice	29 December 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	12 November 2019 - 13 November 2019
No. of securities held prior to change	61,654 Fully Paid Ordinary Shares 50,000,000 Unlisted Restricted Stock Units, LTI Plan 15,000,000 Unlisted Options*
Class	Fully Paid Ordinary Shares
Number acquired	36,111,110 Fully Paid Ordinary Shares
Number disposed	23,470,000 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Acquisition - Nil consideration, issued as part of conversion of Director's Unlisted Restricted Stock Units. Disposal - \$0.59 per share
No. of securities held after change	12,702,764 Ordinary Shares 13,888,890 Unlisted Restricted Stock Units, LTI Plan 15,000,000 Unlisted Options*
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acquisition - Conversion of Unlisted Restricted Stock Units, LTI Plan Disposal - On-market sale

* The Unlisted Options were issued to Dr. Michael Perry on 30 November 2018 with the approval of shareholders. Full details were disclosed in the Company's 2018 AGM Notice, the subsequent Appendix 3B and the 2019 Annual Report (including their value); however, an Appendix 3Y was inadvertently not filed at the time of issue.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.